Literature DB >> 18698017

Survivin: key regulator of mitosis and apoptosis and novel target for cancer therapeutics.

Alain C Mita1, Monica M Mita, Steffan T Nawrocki, Francis J Giles.   

Abstract

Survivin, a member of the family of inhibitor of apoptosis proteins, functions as a key regulator of mitosis and programmed cell death. Initially, survivin was described as an inhibitor of caspase-9. However, over the last years, research studies have shown that the role of survivin in cancer pathogenesis is not limited to apoptosis inhibition but also involves the regulation of the mitotic spindle checkpoint and the promotion of angiogenesis and chemoresistance. Survivin gene expression is transcriptionally repressed by wild-type p53 and can be deregulated in cancer by several mechanisms, including gene amplification, hypomethylation, increased promoter activity, and loss of p53 function. This article reviews the multiple functions of survivin in the regulation of apoptosis, the promotion of tumorigenesis, and the development of survivin inhibitors as a novel anticancer therapeutic strategy.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18698017     DOI: 10.1158/1078-0432.CCR-08-0746

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  301 in total

1.  Aging brain microenvironment decreases hippocampal neurogenesis through Wnt-mediated survivin signaling.

Authors:  Carlos J Miranda; Lyndsey Braun; Yuying Jiang; Mark E Hester; Ling Zhang; Matthew Riolo; Haijuan Wang; Meghan Rao; Rachel A Altura; Brian K Kaspar
Journal:  Aging Cell       Date:  2012-04-04       Impact factor: 9.304

2.  Survivin is a potential mediator of prostate cancer metastasis.

Authors:  Min Zhang; John J Coen; Yoshiyuki Suzuki; Michael R Siedow; Andrzej Niemierko; Li-Yan Khor; Alan Pollack; Yifen Zhang; Anthony L Zietman; William U Shipley; Arnab Chakravarti
Journal:  Int J Radiat Oncol Biol Phys       Date:  2010-03-16       Impact factor: 7.038

3.  Protection of CHO cells by transfer of survivin driven by ovarian-specific promoter OSP-2.

Authors:  Chun-Hua Tu; Wei-Peng Liu; Mei Dong; Li-Ping Cai; Ya-Qin Mo; Dong-Zi Yang
Journal:  Mol Biol Rep       Date:  2010-11-14       Impact factor: 2.316

4.  Survivin is not induced by novel taxanes.

Authors:  Nima Sharifi; Jun Qi; Susan Bane; Shubhada Sharma; Rui Li; Robert Robey; William D Figg; William L Farrar; David G I Kingston
Journal:  Mol Pharm       Date:  2010-10-07       Impact factor: 4.939

5.  Expressions of survivin and vascular endothelial growth factor in a Murine model of proliferative retinopathy.

Authors:  Na Cai; Ning-Ning Liu; Ning Zhao; Chao Wan; Yue-Dong Hu; Yun Zhou; Lei Chen
Journal:  Int J Ophthalmol       Date:  2012-06-18       Impact factor: 1.779

Review 6.  Novel therapeutic targets for pancreatic cancer.

Authors:  Shing-Chun Tang; Yang-Chao Chen
Journal:  World J Gastroenterol       Date:  2014-08-21       Impact factor: 5.742

7.  Human embryonic stem cell-derived microvascular grafts for cardiac tissue preservation after myocardial infarction.

Authors:  Thomas P Kraehenbuehl; Lino S Ferreira; Alison M Hayward; Matthias Nahrendorf; André J van der Vlies; Eliza Vasile; Ralph Weissleder; Robert Langer; Jeffrey A Hubbell
Journal:  Biomaterials       Date:  2010-10-28       Impact factor: 12.479

Review 8.  Survivin as a novel target protein for reducing the proliferation of cancer cells.

Authors:  Dongyu Li; Chenghao Hu; Huibin Li
Journal:  Biomed Rep       Date:  2018-03-13

Review 9.  Association of survivin splice variants with prognosis and treatment of breast cancer.

Authors:  Anastasia Pavlidou; Christos Kroupis; Kleanthi Dimas
Journal:  World J Clin Oncol       Date:  2014-12-10

10.  Targeting and eradicating hepatic cancer cells with a cancer-specific vector carrying the Buforin II gene.

Authors:  Yanyun Wang; Lili Qu; Lailing Gong; Li Sun; Rujun Gong; Jin Si
Journal:  Cancer Biother Radiopharm       Date:  2013-06-25       Impact factor: 3.099

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.